Central serous chorioretinopathy treated with mineralocorticoid antagonists a one-year pilot study

Retina

Volumn 36, Issue 3, 2016, Pages 611-618

  Ghadiali, Quraish ^a,b   Jung, Jesse J ^a,b,c,d   Yu, Suqin ^b,c,e   Patel, Samir N ^f   Yannuzzi, Lawrence A ^a,b,c,d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

^c EAR AND THROAT HOSPITAL   (United States)

^d Edward S Harkness Eye Institute   (United States)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Central serous chorioretinopathy; Eplerenone; Mineralocorticoid antagonist; Pachychoroid; Spironolactone

Indexed keywords

EPLERENONE; SPIRONOLACTONE; VASCULOTROPIN ANTIBODY; MINERALOCORTICOID ANTAGONIST;

ADULT; AGED; ARTICLE; CENTRAL MACULAR THICKNESS; CENTRAL SEROUS RETINOPATHY; CHOROID; CHOROIDAL THICKNESS; CLINICAL ARTICLE; DIZZINESS; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELEVATED BLOOD PRESSURE; FEMALE; FOLLOW UP; HUMAN; LOW LEVEL LASER THERAPY; MALE; MULTIMODAL IMAGING; OPTICAL COHERENCE TOMOGRAPHY; PILOT STUDY; RETINA DETACHMENT; RETROSPECTIVE STUDY; SUBRETINAL FLUID; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY; ANALOGS AND DERIVATIVES; CENTRAL SEROUS CHORIORETINOPATHY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AGED; CENTRAL SEROUS CHORIORETINOPATHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MULTIMODAL IMAGING; PILOT PROJECTS; RETROSPECTIVE STUDIES; SPIRONOLACTONE; SUBRETINAL FLUID; VISUAL ACUITY;

EID: 84944351007     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000748     Document Type: Article

References (27)

1. Hayashi K, Hasegawa Y, Tokoro T. Indocyanine green angiography of central serous chorioretinopathy. Int Ophthalmol 1986;9:37-41.
2. Guyer DR, Yannuzzi LA, Slakter JS, et al. Digital indocyanine-green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 1994;112:1057-1062.
3. Prunte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 1996;121:26-34.
4. Gass JD. Specific Diseases Causing Disciform Macular Detachment. Stereoscopic Atlas of Macular Diseases. New York, NY: Mosby; 1997:52-70.
5. Tittl M, Polska E, Kircher K, et al. Topical fundus pulsation measurements in patients with active central serous chorioretinopathy. Arch Ophthalmol 2003;121:975-978.
6. Tittl M, Maar N, Polska E, et al. Choroidal hemodynamic changes during isometric exercise in patients with inactive central serous chorioretinopathy. Invest Ophthalmol Vis Sci 2005;46:4717-4721.
7. Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol 2013;41:201-214.
8. Imamura Y, Fujiwara T, Margolis R, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 2009;29: 1469-1473.
9. Regatieri CV, Branchini L, Fujimoto JG, Duker JS. Choroidal imaging using spectral-domain optical coherence tomography. Retina 2012;32:865-876.
10. Kim SW, Oh J, Kwon SS, et al. Comparison of choroidal thickness among patients with healthy eyes, early age-related maculopathy, neovascular age-related macular degeneration, central serous chorioretinopathy, and polypoidal choroidal vasculopathy. Retina 2011;31:1904-1911.
11. Harada T, Harada K. Six cases of central serous choroidopathy induced by systemic corticosteroid therapy. Doc Ophthalmol 1985;60:37-44.
12. Yannuzzi LA. Type-A behavior and central serous chorioretinopathy. Retina 1987;7:111-131.
13. Bouzas EA, Scott MH, Mastorakos G, et al. Central serous chorioretinopathy in endogenous hypercortisolism. Arch Ophthalmol 1993;111:1229-1233.
14. Garg SP, Dada T, Talwar D, Biswas NR. Endogenous cortisol profile in patients with central serous chorioretinopathy. Br J Ophthalmol 1997;81:962-964.
15. Tittl MK, Spaide RF, Wong D, et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol 1999;128:63-68.
16. Carvalho-Recchia CA, Yannuzzi LA, Negrao S, et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology 2002;109:1834-1837.
17. Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology 2003;110:698-703.
18. Haimovici R, Koh S, Gagnon DR, et al. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 2004;111:244-249.
19. Jonas JB, Kamppeter BA. Intravitreal triamcinolone acetonide and central serous chorioretinopathy. Br J Ophthalmol 2005; 89:386-387.
20. Zhao M, Célérier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest 2012;122:2672-2679.
21. Gruszka A. Potential involvement of mineralocorticoid receptor activation in the pathogenesis of central serous chorioretinopathy: case report. Eur Rev Med Pharmacol Sci 2013;17:1369-1373.
22. Bousquet E, Beydoun T, Zhao M, et al. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2013;33:2095-2102.
23. Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003;23:288-298.
24. Warrow DJ, Hoang QV, Freund KB, et al. Pachychoroid pigment epitheliopathy. Retina 2013;33:1659-1672.
25. Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 2007;31:153-158.
26. Aldactone (Spironolactone) prescribing information. Pfizer; 2010. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/012151s062lbl.pdf. Accessed October 27, 2014.
27. Inspra (Eplerenone) prescribing information. Pfizer; 2013. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/021437s011lbl.pdf. Accessed October 27, 2014.